45.575 USD
+0.44 (+0.96%)
45.575 USD
0 (0%)
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While COLL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, COLL could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
COLL had positive earnings in the past year.
In the past year COLL had a positive cash flow from operations.
COLL had positive earnings in 4 of the past 5 years.
COLL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
COLL's Return On Assets of 3.64% is amongst the best of the industry. COLL outperforms 84.38% of its industry peers.
The Return On Equity of COLL (21.27%) is better than 91.67% of its industry peers.
The Return On Invested Capital of COLL (9.10%) is better than 88.02% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
COLL's Profit Margin of 7.72% is amongst the best of the industry. COLL outperforms 83.33% of its industry peers.
In the last couple of years the Profit Margin of COLL has declined.
COLL's Operating Margin of 20.74% is amongst the best of the industry. COLL outperforms 88.02% of its industry peers.
In the last couple of years the Operating Margin of COLL has grown nicely.
The Gross Margin of COLL (57.22%) is better than 66.67% of its industry peers.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
COLL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for COLL has been reduced compared to 5 years ago.
The debt/assets ratio for COLL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.46, we must say that COLL is in the distress zone and has some risk of bankruptcy.
COLL's Altman-Z score of 1.46 is in line compared to the rest of the industry. COLL outperforms 58.33% of its industry peers.
COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.79, COLL belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
COLL has a Debt to Equity ratio of 2.71. This is amonst the worse of the industry: COLL underperforms 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.46 |
ROIC/WACC1.03
WACC8.84%
2.3 Liquidity
A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, COLL is doing worse than 73.44% of the companies in the same industry.
COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.27, COLL is not doing good in the industry: 70.83% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.73% over the past year.
COLL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 154.78% yearly.
Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.58% yearly.
Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 3.62% on average per year.
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
COLL is valuated cheaply with a Price/Earnings ratio of 6.34.
Compared to the rest of the industry, the Price/Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.79% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.65. COLL is valued rather cheaply when compared to this.
COLL is valuated cheaply with a Price/Forward Earnings ratio of 5.36.
Compared to the rest of the industry, the Price/Forward Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 95.83% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.45, COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.34 | ||
| Fwd PE | 5.36 |
4.2 Price Multiples
97.92% of the companies in the same industry are more expensive than COLL, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 95.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.98 | ||
| EV/EBITDA | 4.77 |
4.3 Compensation for Growth
COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y5.61%
5. Dividend
5.1 Amount
COLL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.575
+0.44 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change0.64%
Ins Owners1.56%
Ins Owner Change-0.63%
Market Cap1.44B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target47.74 (4.75%)
Short Float %17.38%
Short Ratio12.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)4.93%
PT rev (3m)5.88%
EPS NQ rev (1m)7.86%
EPS NQ rev (3m)8.88%
EPS NY rev (1m)0%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)5.8%
Revenue NQ rev (3m)4%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.34 | ||
| Fwd PE | 5.36 | ||
| P/S | 1.9 | ||
| P/FCF | 4.98 | ||
| P/OCF | 4.95 | ||
| P/B | 5.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.77 |
EPS(TTM)7.19
EY15.78%
EPS(NY)8.51
Fwd EY18.66%
FCF(TTM)9.15
FCFY20.08%
OCF(TTM)9.2
OCFY20.19%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.16
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.46 |
F-Score7
WACC8.84%
ROIC/WACC1.03
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.